• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
By ARMIE MARGARET LEE Nov 27, 2017 | 09:30 AM EST
Stocks quotes in this article: ALKS, CPRX, BNTC, BIIB

Shares of Alkermes Plc (ALKS) gained 5.2% to $53.72 in premarket trading on Monday, Nov. 27, as the Dublin-based firm and Biogen Inc. (BIIB) inked a global license and collaboration pact to develop and commercialize ALKS 8700, which is in Phase 3 development for the treatment of relapsing forms of multiple sclerosis.

The agreement gives Cambridge, Mass.-based Biogen an exclusive, worldwide license to commercialize ALKS 8700. Biogen will pay Alkermes a mid-teens royalty on worldwide net sales of the drug.

As part of the agreement, Biogen will reimburse Alkermes for 50% of the 2017 development costs for the drug, with Alkermes receiving an upfront payment of $28 million representing Biogen's share of development expenses already incurred in 2017. Starting January of next year, Biogen will shoulder all development expenses for ALKS 8700.

Alkermes may also receive milestone payments of up to $200 million for ALKS 8700.

Meanwhile, shares of Catalyst Pharmaceuticals Inc.  (CPRX) rose 8.3% to $3.79 after the Coral Gables, Fla.-based firm unveiled positive top-line results from its second Phase 3 study of Firdapse for the symptomatic treatment of Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder often characterized by muscle weakness of the limbs.

Catalyst president and CEO Patrick J. McEnany said in a statement that the company remains on pace to submit its new drug application to the U.S. Food and Drug Administration in the first quarter of next year.

Other biotech movers include Benitec Biopharma Ltd. (BNTC) . Benitec's American depository receipts rose 19.1% to $3.30 after the Sydney-based company said it has submitted an application to the FDA seeking orphan drug designation for BB-301 as a treatment of oculopharyngeal muscular dystrophy, a disease caused by mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene.

"The Benitec team is executing on the key initiatives required to advance BB-301 into human clinical trials and we remain on track with our plan to file an IND with the FDA in the 4th quarter of 2018 and, assuming approval on a normal time-frame, we should be in an initial human clinical study by the end of 2018," said Benitec CEO Greg West in the news release.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Global Equity | Healthcare

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:31 PM EST PETER WILLSON

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • 10:10 AM EST GARY BERMAN

    DLTR: The Buck Might Not Stop Here, but I Am Looking for a Bounce

    Dollar Tree is trading inside our long-term boun...
  • 08:36 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 2/24/2021

    SPX (Long-Term View) The 2/16 HIGH @ 3950.43 is ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login